At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

This was the stock's fourth consecutive day of losses.

A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.

Given the accelerating sales growth of LIBTAYO and stabilization in the EYLEA franchise, investors bid up the price of Regeneron's stock by +4.5% on Tuesday. The company's robust performance makes ...

Secondly, to support the stock price, Regeneron management announced the authorization of an additional $3 billion, which will go towards a share buyback program. The New York-based company ...